Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1286-1291

  Geisler, J ^a   King, N ^b   Dowsett, M ^b   Ottestad, L ^c   Lundgren, S ^d   Walton, P ^e,f   Kormeset, P O ^e,f   Lonning P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e Zeneca Pharmaceuticals   (Norway)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitor; Breast cancer; Hormone therapy

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; TAMOXIFEN;

AROMATIZATION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029804714     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.531     Document Type: Article

References (32)

1. CASH R, BROUGH AJ, COHEN MNP AND SATOH PS. (1967). Aminoglutethimide (Elipten-CIBA) as an inhibitor of adrenal steroidogenesis. Mechanisms of action and therapeutic trial. J. Clin. Endocrinol. Metab., 27, 1239-1248.
2. COOMBES RC, GOSS P, DOWSETT M, GAZET JC AND BRODIE A. (1984). 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet, 2, 1237-1239.
3. DEMERS LM. LIPTON A, HARVEY HA, KAMBIC KB, GROSSBERG H, BRADY C AND SANTEN RJ. (1993). The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J. Steroid Biochem. Mol. Biol., 44, 687-691.
4. DOWSETT M, GOSS PE, POWLES TJ, HUTCHINSON G, BRODIE AMH, JEFFCOATE SL AND COOMBES RC. (1987). Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimisation of dose and route. Cancer Res., 47, 1957-1961.
5. DOWSETT M, CUNNINGHAM DC, STEIN RC, EVANS S, DEHENNIN L. HEDLEY A AND COOMBES RC. (1989). Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res., 49, 1306-1312.
6. DOWSETT M, STEIN RC, MEHTA A AND COOMBES RC. (1990). Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin. Endocrinol., 32, 623-634.
7. DOWSETT M, JONES A, JOHNSTON SRD, JACOBS S, TRUNET PAND SMITH IE (1995). In vivo measurement of aromatase inhibition be letrozole (CGS 20267) in post-menopausal patients with breast cancer. Clin. Cancer Res., 1, 1511-1515.
8. EVANS TRJ, SALLE ED, ORNATI G, LASSUS M, BENEDETTI MS, PIANEZZOLA E AND COOMBES RC. (1992). Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res., 52, 5933-5939.
9. HOTSIS T AND ADLERCREUTZ H. (1987). The multicomponent analysis of oestrogens in urine by ion exchange chromatography and GC-MS-1. Quantitation of oeslrogens after initial hydrolysis of conjugates. J. Steroid Biochem. Mol. Biol., 28, 203-213.
10. GRODIN JM, SIITERI PK AND MCDONALD PC. (1973). Source of estrogen production in postmenopausal women. J. Clin. Endocrinol. Metab., 36, 207-214.
11. IVESON TJ, SMITH IE, AHERN J, SMITHERS DA, TRUNET PF AND DOWSETT M. (1993). Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J. Clin. Endocrinol. Metab., 77, 324-331.
12. JACOBS S, LØNNING PE, HAYNES B, GRIGIGS L AND DOWSETT M. (1991). Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J. Enzyme Inhib., 4, 315-325.
13. HNSTON SRD, SMITH IE, DOODY D, JACOBS S, ROBERTSHAW H AND DOWSETT M. (1994). Clinical and endocrine effects of the oral aromatase inhibitor vorozole in post-menopausul patients with advanced breast cancer. Cancer Res., 54, 5875-5881.
14. JONES AL, MACNEILL F, JACOBS S, LØNNING PE, DOWSETT M AND POWLES TJ, (1992). The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur. J. Cancer, 28A, 1712-1716.
15. LIPTON A, DEMERS LM, HARVEY HA, KAMBIC KB, GROSSBERG, H, BRADY C, ADLERCREUTZ H, TRUNET PF AND SANTEN RJ. (1995). Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer, 75, 2132-2138.
16. LØNNING PE AND EKSE D. (1995). A sensitive assay for measurement of plasma oestrone sulphate in patients on treatment with aromatase inhibitors. J. Steroid Biochem. Mol. Biol., 55, 409-412.
17. LØNNING PE AND KVINNSLAND S, (1998). Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs, 35, 685-710.
18. LØNNING PE, DOWSETT M AND POWLES TJ. (1990). Postmenopausal oestrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J. Steroid Biochem. Mol. Biol., 35, 355-366.
19. LØNNING PE, JACOBS S, JONES A, HAYNES B, POWLES T AND DOWSETT M. (1991). The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br. J. Cancer, 63, 789-793.
20. LØNNING, PE, HELLE SI, JOHANNESSEN DC, ADLERCREUTZ H, LIEN EA, TALLY M, EKSE D, FOTSIS T, ANKER GB AND HALL K. (1995). Relations between sex hormones, sex hormone binding globulin. insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin. Endocrinol., 42, 23-30.
21. MACNEILL FA, JONES AL, JACOBS S, LØNNING PE, POWLES TJ AND DOWSETT M. (1992). The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br. J. Cancer, 66, 692-697.
22. MASAMURA S, ADLERCREUTZ H, HARVEY H, LIPTON A, DEMERS LM, SANTEN RJ AND SANTNER SJ. (1994). Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res. Treat., 33, 19-26.
23. PLOURDE PV, DYROFF M AND DUKES M. (1994). Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat., 30, 103-111.
24. PLOURDE PV, DYROFF M, DOWSETT M, DEMERS L, YATES R AND WEBSTER A. (1995). Arimidex: a new oral, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol., 53, 175-179.
25. ED MJ, LAI LC, OWEN AM, SINGH A, COLDHAM NG, PUROHIT A, GHILCHIK MW. SHAIKH NA AND JAMES VHT (1990). Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro aromatase activity in postmenopausal women with breast cancer. Cancer Res., 50, 193-196.
26. SANTEN RJ, SANTNER S, DAVIS B, VELDHUIS J, SAMOJLIK E AND RUBY E. (1978). Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab., 47, 1257-1265.
27. SANTEN RJ, SANTNER SJ, TILSEN-MALLETT N, ROSEN HR, SAMOJLIK E AND VELDHUIS JD. (1982a). In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Res., 42 (Suppl.), 3353s-3359s.
28. SANTEN RJ, WORGUL TJ, LIPTON A, HARVEY H AND BOUCHER A. (1982b). Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann. Intern. Med., 96, 94-101.
29. NTEN RJ, DEMERS LM, ADLERCREUTZ H, SANTNER S, SANDERS S AND LIPTON A. (1989). Inhibition of aromatase with CGS 16949A in postmenopausal women. J. Clin. Endocrinol. Metab., 68, 99-106.
30. VERMEULEN A, PARIDAENS R AND HEUSON JC. (1983). Effects of aminoglutethimide on adrenal steroid secretion. Clin. Endocrinol., 19, 673-682.
31. WALL EVD, DONKER TH, FRANKRIJKER ED, NORTIER HWR, THIJSSEN JHH AND BLANKENSTEIN MA. (1993). Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res., 53, 4563-4566.
32. YATES RA, DUKES M, DOWSETT M, DEBERARDINIS M, WILKINSON DM AND WILLIAMS AJ. (1992). Tolerability, pharmacokinetics and effect on serum oestradiol of ICI D 1033, a new aromatase inhibitor. Clin. Pharm. and Ther., Abstract of the Fifth World Conference on Clinical Pharmacology and Therapeutics, Yokohama.